BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 33112553)

  • 41. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevalence and clinical characteristics of myelodysplastic syndrome with bone marrow eosinophilia or basophilia.
    Matsushima T; Handa H; Yokohama A; Nagasaki J; Koiso H; Kin Y; Tanaka Y; Sakura T; Tsukamoto N; Karasawa M; Itoh K; Hirabayashi H; Sawamura M; Shinonome S; Shimano S; Miyawaki S; Nojima Y; Murakami H
    Blood; 2003 May; 101(9):3386-90. PubMed ID: 12506028
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
    Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
    Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
    Warlick ED; Miller JS
    Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High Expression of Human Homologue of Murine Double Minute 4 and the Short Splicing Variant, HDM4-S, in Bone Marrow in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Han X; Medeiros LJ; Zhang YH; You MJ; Andreeff M; Konopleva M; Bueso-Ramos CE
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S30-8. PubMed ID: 27155969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Success in bone marrow failure? Novel therapeutic directions based on the immune environment of myelodysplastic syndromes.
    Cull AH; Rauh MJ
    J Leukoc Biol; 2017 Aug; 102(2):209-219. PubMed ID: 28596252
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Myelodysplastic syndromes: preleukemic syndromes].
    Tassin F; Hermanne JP; Schaaf-Lafontaine N; Herens C; Thiry A; Paulus JM; Boniver J; Fillet G
    Rev Med Liege; 1998 Jun; 53(6):357-62. PubMed ID: 9713217
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success.
    Sloand EM; Barrett AJ
    Hematol Oncol Clin North Am; 2010 Apr; 24(2):331-41. PubMed ID: 20359629
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of Bone Marrow Natural Killer Cells (NK); Soluble TNF-α and IL-32 Levels in Myelodysplastic Syndrome Patients.
    Aref S; Khaled N; Al Gilany AH; Ayed M; Abouzeid T; Attia D
    Asian Pac J Cancer Prev; 2020 Oct; 21(10):2949-2953. PubMed ID: 33112553
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myelodysplastic Syndromes (MDS) and autoimmune disorders (AD): cause or consequence?
    Braun T; Fenaux P
    Best Pract Res Clin Haematol; 2013 Dec; 26(4):327-36. PubMed ID: 24507810
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Surface marker abnormalities in myelodysplastic syndromes.
    Elghetany MT
    Haematologica; 1998 Dec; 83(12):1104-15. PubMed ID: 9949628
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Novel insights into the biology of myelodysplastic syndromes: excessive apoptosis and the role of cytokines.
    Raza A; Mundle S; Shetty V; Alvi S; Chopra H; Span L; Parcharidou A; Dar S; Venugopal P; Borok R; Gezer S; Showel J; Loew J; Robin E; Rifkin S; Alston D; Hernandez B; Shah R; Kaizer H; Gregory S
    Int J Hematol; 1996 Jun; 63(4):265-78. PubMed ID: 8762810
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Interleukin-2 therapy for myelodysplastic syndrome: does it work?
    Ogata K; Yokose N; Nomura T
    Leuk Lymphoma; 1995 May; 17(5-6):411-5. PubMed ID: 7549831
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A Killer Disarmed: Natural Killer Cell Impairment in Myelodysplastic Syndrome.
    Arellano-Ballestero H; Sabry M; Lowdell MW
    Cells; 2023 Feb; 12(4):. PubMed ID: 36831300
    [TBL] [Abstract][Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 58.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.